|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Sienna Biopharmaceuticals, Inc. (SNNA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Wed 11/22
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
19,931,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.000001 - $0.0001 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s primary product candidates from its technological platform are SNA-120 (pegcantratinib), a first-in-class TrkA inhibitor for the topical treatment of psoriasis, as well as the associated pruritus; and SNA-125, a topical JAK3/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and the associated pruritus. Co.'s second technology platform, Topical Photoparticle Therapy, utilizes silver particles applied to the skin to direct the light from commercially available lasers to the hair follicle or sebaceous gland to cause selective photothermolysis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Azoy Alexander |
Chief Financial Officer |
|
2019-10-02 |
4 |
D |
$0.23 |
$551 |
D/D |
(2,396) |
103,552 |
|
- |
|
Beddingfield Iii Frederick |
President & CEO |
|
2019-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
967,599 |
|
- |
|
Azoy Alexander |
Chief Financial Officer |
|
2019-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
105,948 |
|
- |
|
Andrews Timothy K. |
General Counsel & Secretary |
|
2019-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
145,558 |
|
- |
|
Lizzul Paul F. |
Chief Medical Officer |
|
2019-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
196,488 |
|
- |
|
Lizzul Paul F. |
Chief Medical Officer |
|
2019-07-02 |
4 |
D |
$0.76 |
$3,112 |
D/D |
(4,095) |
141,488 |
|
- |
|
Azoy Alexander |
Chief Financial Officer |
|
2019-07-02 |
4 |
D |
$0.76 |
$1,180 |
D/D |
(1,552) |
35,948 |
|
- |
|
Beddingfield Iii Frederick |
President & CEO |
|
2019-07-02 |
4 |
D |
$0.76 |
$12,968 |
D/D |
(17,063) |
817,599 |
|
- |
|
Stroehmann Diane |
See Remarks |
|
2019-07-02 |
4 |
D |
$0.76 |
$3,112 |
D/D |
(4,095) |
168,545 |
|
- |
|
Andrews Timothy K. |
General Counsel & Secretary |
|
2019-07-02 |
4 |
D |
$0.76 |
$3,112 |
D/D |
(4,095) |
95,558 |
|
- |
|
Azoy Alexander |
Chief Financial Officer |
|
2019-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,500 |
|
- |
|
Azoy Alexander |
Chief Financial Officer |
|
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
37,500 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2019-02-22 |
4 |
B |
$2.50 |
$5,414,500 |
I/I |
2,165,800 |
1,865,800 |
1.5 |
- |
|
Burow Kristina |
Director |
|
2019-02-22 |
4 |
B |
$2.50 |
$5,414,500 |
I/I |
2,165,800 |
1,865,800 |
2.1 |
- |
|
More Robert J |
|
|
2019-02-22 |
4 |
B |
$2.50 |
$250,000 |
D/D |
100,000 |
255,942 |
0.01 |
- |
|
Beddingfield Iii Frederick |
President & CEO |
|
2019-02-22 |
4 |
B |
$2.50 |
$100,000 |
D/D |
40,000 |
831,662 |
0.01 |
- |
|
Leonard Keith R |
|
|
2019-02-22 |
4 |
B |
$2.50 |
$250,000 |
D/D |
100,000 |
100,000 |
0.01 |
- |
|
Gillis Steven |
10% Owner |
|
2019-02-22 |
4 |
B |
$2.50 |
$5,414,500 |
I/I |
2,165,800 |
1,865,800 |
1.5 |
- |
|
Beddingfield Iii Frederick |
President & CEO |
|
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
187,500 |
791,662 |
|
- |
|
Lizzul Paul F. |
Chief Medical Officer |
|
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
142,583 |
|
- |
|
Andrews Timothy K. |
General Counsel & Secretary |
|
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
99,653 |
|
- |
|
Smither John W |
Chief Financial Officer |
|
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
46,657 |
|
- |
|
Stroehmann Diane |
See Remarks |
|
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
172,640 |
|
- |
|
Beddingfield Iii Frederick |
President & CEO |
|
2018-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
47,594 |
601,246 |
|
- |
|
Harris Todd |
Head of Corporate Development |
|
2018-04-30 |
4 |
AS |
$20.00 |
$2,000 |
D/D |
(100) |
570,991 |
|
- |
|
61 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|